Ovid Therapeutics Stock Investor Sentiment

OVID Stock  USD 1.09  0.01  0.91%   
About 61% of Ovid Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Ovid Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Ovid Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Ovid Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Ovid Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ovid Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at news.google.com         
Ovid Therapeutics Inc. Receives Consensus Rating of Moderate Buy from Analysts - MarketBeat
Google News at Macroaxis
few days ago at thelincolnianonline.com         
B. Riley Predicts Reduced Earnings for Ovid Therapeutics
news
over a week ago at aol.com         
Analysis-RFK Jr vow to purge FDA sets up collision with Big Pharma
news
over a week ago at gurufocus.com         
Biotechnology Value Fund L Ps Strategic Reduction in Ovid Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at aljazeera.com         
How controversial is Trumps pick of RFK Jr as US health secretary?
news
over a week ago at globenewswire.com         
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over a week ago at zacks.com         
Agenus Reports Q3 Loss, Lags Revenue Estimates
zacks News
over a week ago at investing.com         
Ovid Therapeutics earnings beat, revenue topped estimates
Investing News at Macroaxis
over two weeks ago at aol.com         
Explainer-How Trumps second administration affects business Musk, tariffs and more
news
over two weeks ago at finance.yahoo.com         
Explainer-How Trumps second administration affects business Musk, tariffs and more
Yahoo News
over two weeks ago at finance.yahoo.com         
Explainer-How Trumps second administration affects business Musk, tariffs and more
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Williams Douglas E of 13250 shares of Ovid Therapeutics at 5.29 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Ovid Therapeutics Inc. Given Consensus Recommendation of Moderate Buy by Analysts
news
over a month ago at finance.yahoo.com         
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City
Yahoo News
Far too much social signal, news, headlines, and media speculation about Ovid Therapeutics that are available to investors today. That information is available publicly through Ovid media outlets and privately through word of mouth or via Ovid internal channels. However, regardless of the origin, that massive amount of Ovid data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ovid Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ovid Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ovid Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ovid Therapeutics alpha.

Ovid Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Ovid Therapeutics to Present at Upcoming September Investor Conferences
09/04/2024
2
Disposition of 70000 shares by Alexander Margaret A. of Ovid Therapeutics at 3.73 subject to Rule 16b-3
09/09/2024
3
Ovid Therapeutics Shares Cross Below Fifty Day Moving Average of 1.06 - MarketBeat
09/20/2024
4
Will Ovid Therapeutics Spend Its Cash Wisely
09/30/2024
5
Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3
10/24/2024
6
Acquisition by Williams Douglas E of 13250 shares of Ovid Therapeutics at 5.29 subject to Rule 16b-3
10/25/2024
7
Explainer-How Trumps second administration affects business Musk, tariffs and more
11/06/2024
8
Agenus Reports Q3 Loss, Lags Revenue Estimates
11/12/2024
9
Biotechnology Value Fund L Ps Strategic Reduction in Ovid Therapeutics Inc
11/15/2024

Complementary Tools for Ovid Stock analysis

When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets